Drug Profile

WSD 1227

Alternative Names: WSD-1227

Latest Information Update: 06 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wayshine Biopharma
Class Antineoplastics; Small molecules
Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Brain cancer

Most Recent Events

06 Jan 2025 WSD 1227 is still in preclinical trial in Brain cancer in China (PO) (Wayshine Biopharma pipeline; January 2025)
26 Mar 2019 Pharmacodynamics data from a preclinical study in Brain metastases presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
21 Apr 2018 Preclinical trials in Brain cancer in China (PO) before April 2018

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com